Cubist Pharmaceuticals Incorporated Company Profile - Aug 14, 2011 by WrightReports

VIEWS: 17 PAGES: 11

Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The Company's products are used primarily in hospitals, but also may be used in acute care settings, including home infusion and hospital outpatient clinics. As of December 31, 2010, Cubist's derived all of its revenues from CUBICIN (daptomycin for injection), which is a once-daily, bactericidal, intravenous (I.V.) antibiotic with activity against certain Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (S. aureus), (MRSA). As of December 31, 2010, CUBICIN had been used in the treatment of more than an estimated 1.1 million patients in the United States.

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Cubist Pharmaceuticals Incorporated
                                                                                         440 Wheelers Farms Road
                                                                                         Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in U.S. Dollars

                                 Wright Quality Rating:BBA18                                 Key Data

   Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on           Ticker:
   the research, development and commercialization of pharmaceutical products that           CBST
   address unmet medical needs in the acute care environment. The Company's
   products are used primarily in hospitals, but also may be used in acute care settings,    2010 Sales:
   including home infusion and hospital outpatient clinics. As of December 31, 2010,
                                                                                             636,458,000
   Cubist's derived all of its revenues from CUBICIN (daptomycin for injection), which is
   a once-daily, bactericidal, intravenous (I.V.) antibiotic with activity against certain
   Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (S.        Major Industry:
   aureus), (MRSA). As of December 31, 2010, CUBICIN had been used in the treatment          Drugs, Cosmetics & Health
   of more than an estimated 1.1 million patients in the United States.                      Care
                       Stock Chart                                Officers
                                                           Non Executive Chairman            Sub Industry:
                                                               Kenneth M. Bate               Ethical Drug Manufacturers

                                                          President & Chief Executive        Country:
                                                               Michael W. Bonney             United States

                                                          Executive Vice President &         Currency:
                                                           Chief Operating Officer           U.S. Dollars
                                                                Robert J. Perez
                                                                                             Fiscal Year Ends:
                                                               Senior Vice President &
                                                                                             December
                                                               Chief Financial Officer
                                                                  David W.J. McGirr
                                                                                             Employees
                                                                                             638
                                                            Senior Vice President,
                                                         Secretary & General Counsel
                                                               Tamara L. Joseph      Exchanges:
                                                                                     NAS

                                                                               
								
To top